Registered title, quoted from ClinicalTrials.gov
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07784309, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 9
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (9 points)Hide the checklist
3 years to 70 years; sex: all
Registered eligibility fields
By flow cytometry, tumor cells expressing CD7 account for ≥80%; or confirmed by immunohistochemistry, tumor cells expressing CD7 account for ≥30%;
Inclusion criterion 4
During the screening period, acute T lymphoblastic leukemia/lymphoblastic lymphoma and acute myeloid leukemia must meet the requirement that the proportion of bone marrow blasts and immature lymphocytes is ≥5%; extramedullary lesions or non-Hodgkin lymphoma must have measurable lesions on imaging: the longest diameter of nodal lesions must be greater than 1.5 cm, and the longest diameter of extranodal lesions must be greater than 1.0 cm (see "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification").
Inclusion criterion 5
The subjects whose partners are fertile agree to use effective contraceptive measures throughout the treatment period and for 24 months after the treatment, and during this period, they are not allowed to donate eggs/sperm for assisted reproduction. Female subjects of childbearing age (women who have undergone sterilization surgery or have been menopausal for ≥12 months are not considered fertile) have negative urine pregnancy or blood pregnancy tests during the screening period.
Inclusion criterion 13
Previous treatment with anti-CD7 therapy;
Exclusion criterion 22
Participation in other interventional clinical studies within 1 month prior to cell reinfusion, receipt of active investigational drug treatment, or intentional participation in another clinical trial or receiving antitumor treatment not specified in the protocol during the study;
Exclusion criterion 25
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 or Lansky/Karnofsky performance score≥60;
Inclusion criterion 6
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN);
Inclusion criterion 8
Total serum bilirubin ≤ 2 × ULN, unless accompanied by Gilbert's syndrome; patients with Gilbert's syndrome can be included if total bilirubin ≤ 3 × ULN and direct bilirubin ≤ 1.5 × ULN.
Inclusion criterion 9
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min/1.73 m² (Cockcroft and Gault formula);
Inclusion criterion 10
International normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN;
Inclusion criterion 12
Patients with active central nervous system (CNS) leukemia or CNS involvement of lymphoma (CNS-3 as defined by NCCN guidelines, or CNS-2 with neurological symptoms), and without other active central nervous system diseases (such as epilepsy, cerebrovascular disease, etc.) or psychiatric disorders; (patients with CNS disease symptoms must undergo lumbar puncture and MRI to rule out CNS infiltration).
Exclusion criterion 1
Positive hepatitis B surface antigen (HBsAg) or detectable HBV DNA, positive hepatitis C antibody (HCV-Ab), positive syphilis treponemal antibody (TP-Ab), positive HIV antibody; EBV DNA or CMV DNA above the detection limit, meeting any one of these criteria.
Exclusion criterion 8
Pregnant or breastfeeding women.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07784309, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients who voluntarily signs the informed consent form;
- Age 3 and 70 years, any gender;
- Diagnosed with CD7-positive refractory or relapsed hematologic malignancies (including acute T-lymphoblastic leukemia/lymphoblastic lymphoma, acute myeloid leukemia, NK- or T-cell-derived non-Hodgkin lymphoma, etc.);
- By flow cytometry, tumor cells expressing CD7 account for ≥80%; or confirmed by immunohistochemistry, tumor cells expressing CD7 account for ≥30%;
- During the screening period, acute T lymphoblastic leukemia/lymphoblastic lymphoma and acute myeloid leukemia must meet the requirement that the proportion of bone marrow blasts and immature lymphocytes is ≥5%; extramedullary lesions or non-Hodgkin lymphoma must have measurable lesions on imaging: the longest diameter of nodal lesions must be greater than 1.5 cm, and the longest diameter of extranodal lesions must be greater than 1.0 cm (see "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification").
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 or Lansky/Karnofsky performance score≥60;
- Adequate organ function, meeting the following criteria (except for liver function abnormalities caused by tumor infiltration):
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN);
- Total serum bilirubin ≤ 2 × ULN, unless accompanied by Gilbert's syndrome; patients with Gilbert's syndrome can be included if total bilirubin ≤ 3 × ULN and direct bilirubin ≤ 1.5 × ULN.
- Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min/1.73 m² (Cockcroft and Gault formula);
- Minimum pulmonary reserve, defined as ≤ grade 1 dyspnea and blood oxygen saturation > 91% without supplemental oxygen;
- International normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN;
- The subjects whose partners are fertile agree to use effective contraceptive measures throughout the treatment period and for 24 months after the treatment, and during this period, they are not allowed to donate eggs/sperm for assisted reproduction. Female subjects of childbearing age (women who have undergone sterilization surgery or have been menopausal for ≥12 months are not considered fertile) have negative urine pregnancy or blood pregnancy tests during the screening period.
- Willing to undergo hematopoietic stem cell transplantation.
Exclusion Criteria:
- Patients with active central nervous system (CNS) leukemia or CNS involvement of lymphoma (CNS-3 as defined by NCCN guidelines, or CNS-2 with neurological symptoms), and without other active central nervous system diseases (such as epilepsy, cerebrovascular disease, etc.) or psychiatric disorders; (patients with CNS disease symptoms must undergo lumbar puncture and MRI to rule out CNS infiltration).
- Patients with genetic syndromes associated with bone marrow failure, such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndromes.
- Patients who had acute graft-versus-host disease (GvHD) or moderate to severe extensive chronic GvHD within 4 weeks prior to screening.
- Pregnant or breastfeeding women.
- Active systemic autoimmune diseases or connective tissue diseases;
- Active bleeding;
- Concurrent active infection during the screening period (such as sepsis, bacteremia, fungemia, uncontrolled pulmonary infection, and active tuberculosis) that requires treatment;
- Positive hepatitis B surface antigen (HBsAg) or detectable HBV DNA, positive hepatitis C antibody (HCV-Ab), positive syphilis treponemal antibody (TP-Ab), positive HIV antibody; EBV DNA or CMV DNA above the detection limit, meeting any one of these criteria.
- Major surgery within 4 weeks prior to screening, deemed unsuitable for enrollment by the investigator.
- History of or current other malignancies within the past five years, except for tumors with negligible risk of metastasis or death and considered curable, such as adequately treated cervical carcinoma in situ, basal cell carcinoma of the skin, etc.
- The patient's cardiovascular system meets any of the following conditions:
- Left ventricular ejection fraction (LVEF) ≤45% (ECHO);
- New York Heart Association (NYHA) class III or IV congestive heart failure;
- Serious arrhythmias requiring treatment, including QTc interval ≥480 ms (QTcB = QT/RR\^1/2);
- Uncontrolled hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg), pulmonary hypertension, or unstable angina;
- History of myocardial infarction or coronary artery bypass grafting/stent placement within 12 months prior to administration;
- Clinically significant valvular disease;
- Other cardiac conditions deemed unsuitable for enrollment by the investigator.
- Presence of clinically significant pleural effusion, pericardial effusion, or ascites during screening;
- Known hypersensitivity to any component of the study drug;
- Vaccination with live vaccines within 6 weeks prior to screening;
- Previous treatment with anti-CD7 therapy;
- Expected life expectancy of less than 3 months;
- History of solid organ transplantation;
- Participation in other interventional clinical studies within 1 month prior to cell reinfusion, receipt of active investigational drug treatment, or intentional participation in another clinical trial or receiving antitumor treatment not specified in the protocol during the study;
- Other situations deemed by the investigator as unsuitable for participation in this clinical trial.
Quoted from ClinicalTrials.gov, NCT07784309, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07784309, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.